

CURRICULUM VITAE

Surname:	Horáček	Forename:	Jiří
Date of birth:	27/09/1966		
Current position title:	Deputy director of NIMH for R&D, National Institute of Mental Health		

Previous positions held:

Date from	Date to	Position	Department/Institution
2015	Present	Deputy director of for R&D	National Institute of Mental Health
2009	Present	Professor of Psychiatry	Charles University, Prague
1995	2009	Physician and Researcher	Prague Psychiatric Center
1992	1995	Physician and Deputy Consultant	Department of Psychiatry, General Hospital Ostrov

Education/training:

Date	Degree	Subject	University/Institution
2009	Professor	Psychiatry	3 rd Medical Faculty, Charles University, Prague
2004	Associated Professor	Psychiatry	3 rd Medical Faculty, Charles University, Prague
2002	Ph.D.	Neuroscience	Charles University, Prague
1999	Certification in psychotherapy	psychotherapy	MH CR
1997	Certification in psychiatry, 2 nd degree	psychiatry	MH CR
1994	Certification in psychiatry, 1 st degree	psychiatry	MH CR

Scientific career to date (namely information with respect of the focus of the project), including key achievements:

Prof. Jiří Horáček, M.D., Ph.D. is a Professor of Psychiatry at the 3rd Faculty of Medicine, Charles University, Prague, Czech Republic. He holds a degree in psychiatry and psychotherapy. He is currently the Deputy Director of the National Institute of Mental Health, Czech Rep.

Prof. MUDr. J. Horacek, PhD is a leading expert in schizophrenia research in Czech Rep. with long experience in brain imaging (PET, fMRI and qEEG), psychiatric genetics and the animal modeling of mental disorders. Prof. Jiří Horáček has been actively involved in 50 scientific research projects. His research activities involve the use of brain imaging (PET, fMRI and qEEG) in the fields of schizophrenia, depression and OCD, psychiatric genetics and the animal modeling of mental disorders.

He is both the editor of several books and the author of more than 150 scientific articles. Prof. Jiří Horáček has received several national and international psychiatric awards from the International Pharmacoo-EEG Society (Werner Hermann Memorial Award), the Czech Neuropsychopharmacological Society and ECNS-ISNIP.

In his productive career he has been awarded the Senior Research Fellow of the Bedfordshire CMHR in association with the University of Cambridge. He is also the President of the Czech Neuropsychopharmacological Society (2015-2017).

J. Horacek has long experience with project management of national and international EU projects including EEA and Norway Grants and the scientific coordination of National Institute of Mental Health, supported by Operational Project of the EU Program „Research and Development for Innovation“(R&D4I).

Scientometric data:

h – index	Number of citations without self-citation
20	1298

Selected top 8 papers (including IF and citation without self-citation):

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20(5):389-409. IF=4,210, 183x

Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008; 32(5):1014-1023.

IF=2,596, 132x

Bubenikova V, Votava M, Horacek J, Palenicek T, Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. *Pharmacol Biochem Behav* 2005; 80(4):591-596. IF=1,970, 52x

Horacek J, Brunovsky M, Novak T, Skrdlantova L, Klirova M, Bubenikova-Valesova V, Krajca V, Tislerova B, Kopecek M, Spaniel F, Mohr P, Hoschl C. Effect of low-frequency rTMS on electromagnetic tomography (LORETA) and regional brain metabolism (PET) in schizophrenia patients with auditory hallucinations. *Neuropsychobiology* 2007; 55(3-4):132-142. **IF= 2,303, 47x**

Horacek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. *Psychoneuroendocrinology* 1999; 24(8):785-797. IF=2,045, 38x

Horacek J, Zavesicka L, Tintera J, Dockery C, Platilova V, Kopecek M, Spaniel F, Bubenikova V, Hoschl C. The effect of tryptophan depletion on brain activation measured by functional magnetic resonance imaging during the Stroop test in healthy subjects. *Physiol Res* 2005; 54(2):235-244. IF=1,806, 25x

Bubenikova-Valesova V, Svoboda J, Horacek J, Sumiyoshi T. Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats. *Psychopharmacology (Berl)* 2010; 212(2):267-276. IF=3,817, 6x

Horacek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality. *Pharmacopsychiatry* 2000; 33 Suppl 1:34-42. IF=2,681, 26x

Selected publications in peer-reviewed journals in the last 5 years (minimum 5; including IF and number of citations without self-citations). Publications are in order with the most important first.

Horacek J, Mikolas P, Tintera J, Novak T, Palenicek T, Brunovsky M, Hoschl C, Alda M. Sad mood induction has an opposite effect on amygdala response to emotional stimuli in euthymic patients with bipolar disorder and healthy controls. *J Psychiatry Neurosci* 2015; 40(2):134-142. IF=5,861, 2x

Fajnerová I, Rodriguez M, Levčík D, Konrádová L, Mikoláš P, Brom C, Stuchlík A, Vlček K, Horáček J. A virtual reality task based on animal research - spatial learning and memory in patients after the first episode of schizophrenia. *Front Behav Neurosci* 2014; 8(157). doi: 10.3389/fnbeh.2014.00157. IF=3,27, 7x.

Spaniel F, Tintera J, Rydlo J, Ibrahim I, Kasperek T, Horacek J, Zaytseva Y, Matejka M, Fialova M, Slovakova A, Mikolas P, Melicher T, Gornerova N, Hoschl C, Hajek T. Altered Neural Correlate of the Self-Agency Experience in First-Episode Schizophrenia-Spectrum Patients: An fMRI Study. *Schizophr Bull* 2015. IF=8,450, 0x

Melicher T, Horacek J, Hlinka J, Spaniel F, Tintera J, Ibrahim I, Mikolas P, Novak T, Mohr P, Hoschl C. White matter changes in first episode psychosis and their relation to the size of sample studied: a DTI study. *Schizophr Res* 2015; 162(1-3):22-28. IF=3,923, 3x

Kubesova A, Tejkalova H, Syslova K, Kacer P, Vondrousova J, Tyls F, Fujakova M, Palenicek T, Horacek J. Biochemical, histopathological and morphological profiling of a rat model of early

immune stimulation: relation to psychopathology. PLoS One 2015; 10(1):e0115439. IF=3,234, 2x

Research grants in the position of principal or co-principal investigator in the last 5 years (start and end dates of support, title of the project, name of the awarding body, amounts awarded in Euro per the whole period of the grant).

2015 – 2017: “Affective response in visual arts: linking art history and neuroscience perspectives” GAČR 15-08577S (PI Kesner, Co-PI Horáček) Udělené finanční prostředky 4.185 tis. Kč

2016 – 2019: “Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma” AZV 16-29857A (PI Kozák, Co-PI Horáček) Udělené finanční prostředky 22.008 tis. Kč

2015 – 2018: “Pathophysiological constituents of neuronal circuits in OCD: Translational study targeting glutamatergic regulation in the anterior cingulate cortex” AZV 15-34524A (PI Horáček) Udělené finanční prostředky 16.884 tis. Kč.

2012-2015: “The influence of immune system dysregulation and latent toxoplasmosis on brain morphology in schizophrenia: animal models and a prospective volumetric study in patients” IGA MZ NT/1384 (PI Horáček) Udělené finanční prostředky 8.982 tis. Kč.

2014-2017 “HCENAT - Naturalness in human cognitive enhancement “ EHP Norsko 7F14236 (PI Žáčková, Co-PI Horáček) Udělené finanční prostředky 9.565 tis. Kč.

2013 -2015: “Personality and spontaneous brain activity during rest and movie watching: relation and structural determinants” GAČR P407/13-23940S (PI Hlinka, Co-PI Horáček) Udělené finanční prostředky 6.910 tis. Kč.

Patents and collaboration with industry (with respect of the focus of the project).

J. Horacek’s collaboration with industry with respect to the focus of CINTEG:

Company: Konomed, Ltd., **Subject of cooperation:** development in the field of pharmacology and new drugs research

Company: Stapro. **Subject of cooperation:** development of hospital information system (NIS).

Company: GenoMac, , Ltd. **Subject of cooperation:** development and testing of methods for genetic analysis. In the period 2014-2015 extended on research on gDNA separation for determining HumanOmniExpress BeadChip array covering the entire genome of patients and examinations. The cooperation resulted in the following publications: 1) Minarik M, Benesova L, Fantova L, Horacek J, Heracek J, Loukola A (2006). Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections. *Electrophoresis* 27: 3856-3863. 2) Spaniel F, Horacek J, Tintera J, Ibrahim I, Novak T, Cermak J, Klirova M, Hoschl C (2011). Genetic variation in FOXP2 alters grey matter concentrations in schizophrenia patients. *Neurosci Lett* 493: 131-135. 3) Hosak L, Horacek J, Beranek M, Cermakova E (2007). Molecular heterosis in metamphetamine abusers. *Int J Psychiatry Clin Pract* 11: 250-252.

Company: Janssen-Cilag, Ltd. **Subject of cooperation:** joint educational programme “Centre of

advanced studies in psychiatry and psychopharmacology” for the whole CR directly supported by Janssen-Cilag is running from 2015 (<http://www.nudz.cz/files/seminare/seminare.pdf>).

Company: Roche, WN25305. **Description:** Phase III, Multi-Centre, Randomized, 12-Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients with Sub-Optimally Controlled Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 40-Week Double-Blind, Parallel Group, Placebo-Controlled Treatment Period)

Company: Roche, WN25308. Phase III, **Description:** Multi-centre, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients with Persistent, Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period)